title: Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference.
abstract: In the present study, we investigated the effect of aripiprazole, a dopamine system stabilizer, on ethanol-induced psychological and physiological dependence and anxiety-like behavior. First we determined the effect of aripiprazole, a dopamine system stabilizer, on the development and expression of ethanol-induced place preference. Both the development and expression of ethanol-induced place preference was significantly suppressed by treatment of aripiprazole. Next, the withdrawal score gradually increased with increasing duration after the withdrawal from ethanol for 6 days in vehicle-treated mice and the maximal score was observed 10 h after the ethanol withdrawal. Aripiprazole caused no changes in the withdrawal score as compared to vehicle-treated mice. Under these conditions we investigated the effect of aripiprazole on the anxiety-like behavior of ethanol physical dependent mice, which were animals subjected to ethanol vapor for 6 days. The significant decrease of time spent in the open arms and number of open arm entries characterize the anxiety-like behavior in ethanol physical dependent mice, compared to control mice. These decreases were reversed by treatment of aripiprazole, which were inhibited by WAY100635, a serotonin 5-HT(1A) receptor antagonist. The present findings suggest that aripiprazole was efficient for reversing ethanol-induced place preference and anxiety-like behavior.
authors.affiliation: Department of Pharmacology, Kawasaki Medical School, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Shibasaki
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Kurokawa
authors.forename: Koji
authors.initials: K
authors.lastname: Mizuno
authors.forename: Seitaro
authors.initials: S
authors.lastname: Ohkuma
mesh_terms: D000437:Alcoholism / Q000503:physiopathology*; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001007:Anxiety / Q000139:chemically induced / Q000188:drug therapy*; D000068180:Aripiprazole; D001522:Behavior, Animal / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D000431:Ethanol / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D051379:Mice; D010879:Piperazines / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology*; D013375:Substance Withdrawal Syndrome / Q000523:psychology; D013997:Time Factors
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D011725:Pyridines; D015363:Quinolones; D000431:Ethanol; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; D000068180:Aripiprazole; D004298:Dopamine